Hepatitis B And C In Hematopoietic Stem Cell Transplant
2009

Hepatitis B and C in Hematopoietic Stem Cell Transplant

Sample size: 193 publication Evidence: moderate

Author Information

Author(s): Anna Locasciulli, Barbara Montante, Emanuela Morelli, Virginia Gulino, Anna Proia, Maria Beatrice Pinazzi

Primary Institution: San Camillo Hospital

Conclusion

Patients undergoing stem cell transplantation are at risk for hepatitis B and C reactivation, which can lead to severe liver complications.

Supporting Evidence

  • More than sixty percent of HBsAg-positive patients reactivate after transplant.
  • 3% of patients develop acute severe liver failure post-transplant.
  • 81% risk of hepatitis B reactivation at 24 months after allogeneic HSCT.

Takeaway

This study shows that people who get stem cell transplants can get sick from hepatitis B or C, which can hurt their liver.

Methodology

The study reviewed cases of patients undergoing HSCT and analyzed the prevalence and outcomes of HBV and HCV infections.

Limitations

The study may not account for all geographic variations in HBV and HCV prevalence.

Participant Demographics

Patients undergoing allogeneic or autologous stem cell transplantation.

Statistical Information

P-Value

0.3

Statistical Significance

p = 0.3

Digital Object Identifier (DOI)

10.4084/MJHID.2009.016

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication